Bliss GVS Pharma
BLISSGVS · Pharma > Pharmaceuticals & Drugs · Chairman: S R Vaidya · MD: Gagan Harsh Sharma · Listing date: July 26, 2010 · Employees: 683 · Mumbai · http://www.blissgvs.com

Stock Price vs Company Growth
1d
4.1%
1w
6.8%
1m
16.7%
3m
0.7%
6m
3.5%
1y
2.5%
5y
0.3%
10y
2.9%
all
9.5%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowDec10Jun14Dec17Jun21Latest

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

135 4.1%
122
185
Company Overview

Sales
810 Cr
Growth: 5.6%
Profit after Tax
59.6 Cr
Growth: -6.0%
Small Cap
1,422 Cr
P/E: 24.0x
Industry P/E: 29.8x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals

Sales (Cr) ₹ 810
Growth 5.6%
EBITDA 16.5%
P/S 1.8x
Dividend 0.6%
P/E 24.0x
Book Value ₹ 1
PEG Ratio 4.3x
ROE 567.6%
P/B N/A
Shareholding Pattern

Institutions
Arian Investment Ltd
9.7 %
Life Insurance Corporation Of India
6.68 %
Polus Global Fund
4.62 %
Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund
2.9 %
Aspire Emerging Fund
2.46 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep22Dec22Dec23Jun24Sep24
Promoters
Narsimha Shibroor Kamath
33.24 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep22Dec22Dec23Jun24Sep24
Others
Gulbarga Trading And Investment Pvt. Ltd.
5.67 %
Arjun Gautam Ashra
4.89 %
Gautam Rasiklal Ashra
2.82 %
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs
2.2 %
Llp
0.05 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Sep22Dec22Dec23Jun24Sep24
Increase    Decrease    No change
Company Profile Detailed

It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception.
Investors (60)
Followers (10)